Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Biological Chemistry|October 10, 2019
Functionally critical residues in the aminoglycoside resistance-associated methyltransferase RmtC play distinct roles in 30S substrate recognitionMeisam Nosrati, Debayan Dey, Atousa Mehrani, et al.Journal of the American Chemical Society|December 24, 2014
"Turn-on" protein fluorescence: in situ formation of cyanine dyesIpek Yapici, Kin Sing Stephen Lee, Tetyana Berbasova, et al.Acta Crystallographica. Section D, Structural Biology|May 27, 2026
Photoisomerization detected in a fully wavelength-tunable rhodopsin mimic systemNona Ehyaei, Courtney Bingham, Katelyn Silva, et al.Journal of the American Chemical Society|September 27, 2019
Engineering the hCRBPII Domain-Swapped Dimer into a New Class of Protein SwitchesAlireza Ghanbarpour, Cody Pinger, Rahele Esmatpour Salmani, et al.Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.Pageof 2